Introduction
Children suffer pain similar to adults. Besides developmental differences, they exhibit exaggerated emotional and behavioral components of pain including higher anxiety and altered coping mechanisms compared with adults. 1 Although the practice of pediatric pain management has made great progress in the last decade with the development and validation of pain assessment tools specific to children, 2 acute pain remains underrecognized and undertreated even in hospitalized children. 3 Parental behavior and misconceptions regarding pain medications, including fear of opioid addiction, fear of serious adverse drug effects, difficulties in assessment of pain, and lack of advocacy constitute reasons for this suboptimal alleviation of pain among this population. A national survey of 252 institutions found that only 51% had a pediatric pain management service, the practices and supervision of which were influenced by patient characteristics, institutional demographics, and published national guidelines. 4 At our institution, a pain management service initiated in the early 1990s has over the years matured into full-fledged divisions encompassing specific inpatient and outpatient services for perioperative pain, medical pain, chronic pain, and palliative care in addition to education of pain in the core pediatric anesthesia fellowship as well as advanced fellowships in chronic medical pain and palliative care. Our perioperative pain service provides 24/7 coverage with an advanced practice nurse and 1 rotating pediatric anesthesia fellow during the day and 1 nurse trained in pain and a cross-covering anesthesia fellow during the night, under the overall supervision of a faculty member. In fiscal year 2011, we performed >4000 consultations including 750 regional analgesia procedures.
In this chapter, we will discuss limitations of currently popular modalities including patient-controlled analgesia (PCA), protocols for the management of pain after pectus excavatum, and scoliosis surgeries and the pharmacology of newly available analgesics like intravenous (IV) acetaminophen in children. We will also review current literature regarding developmental neurobiology and pharmacology in relation to neonatal/fetal pain and neurotoxicity of analgesia to the developing brain. Finally, we will introduce concepts related to pain genetics and the effects of genetic variations on pharmacokinetics and pharmacodynamics of analgesics, especially opioids.
Limitations of Currently Used Analgesic Modalities
Although there has been a steady increase in regional analgesic techniques including neuraxial and peripheral nerve blocks for pediatric pain management, PCA remains the most common method of providing opioid analgesia in children. 5 PCA is controlled by the patient or a proxy (usually the guardian or the nurse). Two main controversies currently exist related to PCA use in children. 1. PCA by proxy: The Joint Commission issued a sentinel alert in 2004 cautioning against this practice, in which the nurse or parent pushes the PCA button to keep the child comfortable (http://www.jointcom mission.org/assets/1/18/SEA_33.PDF), bypassing the safety feature of the PCA, wherein an oversedated patient cannot push the button. Keeping this in mind, it is essential to have criteria for selecting appropriate patients to receive PCA by proxy. Most children are able to play computer games (by age 6 y) and can understand the PCA/ "pain relief button." At our institution, children less than 6 years of age and those with mental or disability (preventing pushing of the button) often receive PCA by proxy (nurse and/or a responsible parent). The pain management team, recovery room, and inpatient floor nurses educate family members and provide written instructions regarding the proper use of PCA by proxy emphasizing the danger of pressing the button when the child is not awake. Proxycontrolled analgesia has been found to provide effective pain relief in children less than 6 years of age, although 1.7% incidence of significant apnea/desaturation reinforces the need for patient monitoring. 6 With the use of modified Ramsay sedation scale monitoring and use of IV acetaminophen and ketorolac in eligible patients, at our institution, the incidence of severe respiratory depression is <1 per 1000 children (0.1% incidence are not supported by evidence, whereas a basal infusion is particularly useful at night to promote restful sleep by preventing arousal from pain among children. Yildiz et al 7 reported that by decreasing the bolus dose by 50% and using a basal infusion, the total opioid consumption was actually lower compared with bolus dosing alone, with no statistical differences in pain, sedation, and nausea scores between the 2 regimens. However, monitoring for potential overdosage remains necessary. 8 These monitors include nurse use of modified Ramsay or other validated sedation scales every 2 to 4 h), history and physical assessment by the pain team 2 to 3 times/d on rounds, use of pulse oximetry, respiratory rate monitoring (capnography), and protocols for early interventions (eg, stopping continuous infusions, lowering opioid doses).
It is also imperative to establish standards for meaningful pain control. Although pain scores are validated measures of pain assessment, there is significant associated subjectivity. Involving the parents/caretaker to establish clearly how to assess pain in a nonverbal child with multiple medical issues and baseline agitation requires a detailed conversation with the parents and interaction with the child preoperatively. The more valid questions would be whether the analgesia is satisfactory or not for the individual with no significant adverse effects; and whether the patient is able to appropriately mobilize and function or not. The goal of postoperative analgesia is not to eliminate pain, but rather to facilitate rapid return to normal activity levels, prevent transformation of postoperative pain to chronic pain and hyperalgesia, and to improve overall surgical recovery and outcomes. Hence, assessment and adequate relief of dynamic pain during mobilization, deep breathing (incentive spirometry or bubble blowing), and coughing are important. 9 Safe PCA administration to children also requires implementation of protocols for preparation, storage, and dispersement of the drug (pharmacy), pump programming and education (nursing), computerized error-proof drug ordering (physicians), written and verbal education to the caregiver and/or child, close and continuous monitoring, and timely tailoring of management to the child's condition and opioid requirements.
Surgery-specific Analgesia Protocols
The Nuss procedure for pectus excavatum and spinal fusion for scoliosis surgical procedures incur particularly severe pain, which if not well controlled, often leads to persistent chest and back pain. 10, 11 In our institution, for the Nuss procedure, thoracic epidural catheter (T5, T6) is inserted intraoperatively and 0.2% ropivacaine with fentanyl 2 mcg/ mL and/or clonidine 2 mcg/mL is infused postoperatively for 2 to 3 days. Rarely, a PCA is added for cases of insufficient pain control with epidural after excluding opioids from the epidural. Oral medications are begun on the second postoperative day with a controlled-release oral formulation (oxycontin) and on the third postoperative day, the epidural is discontinued and short-acting oral opioid (oxycodone or hydromorphone) is added. These patients experience muscle spasm and anxiety which are treated with IV methocarbamol every 8 hours and diazepam every 6 hours as needed. IV acetaminophen and ketorolac play a significant role in minimizing opioid requirements in patients with normal renal and liver function and minimal risk for bleeding, and can be converted to oral formulations on postoperative day 2 or 3. PCA, interpleural analgesia, and intercostal blocks are other modalities for management of chest pain after minimally invasive pectus surgery, and may be efficient, although use of epidural has been found to provide better pain control in some studies. [12] [13] [14] After spinal fusion surgeries, we employ PCA morphine or hydromorphone or fentanyl depending on the age and comorbidities of the patient. Methocarbamol, diazepam, IV acetaminophen (up to 3 days), and ketorolac (for 2 days) also are an important part of the analgesic armamentarium. A meta-analysis concluded that the use of epidural analgesia in adolescents undergoing scoliosis surgery improves pain control and reduces side effects. 15 A recent systematic review of analgesia after major spine surgery has shown a lack of evidence for overall benefit on postoperative pain control with most regional analgesic techniques, gabapentinoids, and nonsteroidal anti-inflammatory drugs (NSAIDs) after spine surgery 16 ; the authors recommended the use of methadone (0.2 mg/kg) and intraoperative ketamine (0.5 mg/kg IV bolus, followed by infusion at 2 mg/kg/min). 16 We use a combination of ketamine+ morphine PCA (1 mg/mL each) for those postoperative patients who have pain refractory to morphine PCA despite increase in doses/change of opioid, and are dosed according to morphine PCA dosing (20 mcg/kg boluses, 8 to 10 min lockout interval with or without 10 mcg/kg/h infusions).
Alternatives to Opioids
The narrow therapeutic indices of current analgesics necessitate the quest for safer analgesics. A national survey of PCA/proxy-controlled analgesia practices in children less than 6 years of age reported 42 incidents of naloxone administration for cardiorespiratory depression after morphine and 8 deaths over 5 years. 4 Despite the opioid sparing efforts with multimodal therapy, the incidence of mild to moderate clinical respiratory depression defined by respiratory rate <10/min and persistent oxygen saturation <90% on room air is 30% in adolescents undergoing spine fusion at our institution. Our practice uses agonistantagonist opioids in PCA for patients sensitive to opioid-induced respiratory depression such as butorphanol in doses of 5 mg/kg bolus and 0 to 3 mg/kg continuous infusions. For mild to moderate pruritus, we often use nalbuphine 50 mg/kg doses, but for patients who have severe pruritis, low-dose (0.25 to 1 mg/kg/h) naloxone infusions are employed. 17 Constipation, a common opioid side effect, slows recovery and remains difficult to treat. The use of stool softeners (docusate sodium), stimulant (senna, bisacodyl), and osmotic (lactulose) laxatives are the mainstay of therapy and prevention. There is growing evidence that peripherally acting m-antagonists, methylnaltrexone in doses of 0.15 mg/kg subcutaneously, and oral alvimopan of 6 or 12 mg can effectively treat opioidinduced bowel dysfunction 18, 19 ; these peripheral opioid antagonists are especially useful in patients needing opioids for >1-wk duration and having refractory constipation, although they are not used in acute pediatric pain practice presently.
Nonopioid IV adjuvants produce analgesia and decrease opioid dosing but display a "ceiling effect" on analgesia, irrespective of the dose administered. Their mechanism of action involves inhibition of cyclooxygenases (mainly COX-1) and inhibition of prostaglandin synthesis which also produces side effects of decreased renal function (decreases renal blood flow), gastric mucosal irritation (affects protective stomach mucosal lining), decreased platelet activity, and delayed bone healing.
The quest for specific COX-2 inhibitors without these adverse effects has been hampered by the cardiovascular risks of rofecoxib, a Cox-2 inhibitor, which has subsequently been withdrawn from the market. The Food and Drug Administration (FDA) has approved ketorolac for use in children older than 2 years of age, although data describing its safe use in neonates and infants exists. 20 Neonates less than 21 days of life have estimated glomerular filtration rate of <30 mL/min/1.73 m 2 , resulting in markedly delayed drug clearance, which could explain why a retrospective review of ketorolac use in 57 infants aged 0 to 3 months found an increased bleeding in infants less than 21 days of age (or less than 37 wk gestational age). 21 Although we administer ketorolac to children above the age of 1 month who do not have a surgical or medical contraindication (kidney disease, abnormal coagulation profile, hypoperfusion), we restrict the administration to a maximum of 2 days and check renal blood chemistries and urine output.
IV acetaminophen, commonly used at our institution since its approval by the FDA in 2010, is a centrally acting cyclooxygenase inhibitor largely devoid of anti-inflammatory effects. The drug is currently cleared for use in adults and children of less than 2 years of age. Studies for FDA approval in younger children are ongoing. IV administration of acetaminophen provides rapid and predictable analgesic and antipyretic efficacy far superior to oral or rectal administration. IV acetaminophen produces a higher peak serum concentration along with a more rapid decay in serum concentrations than oral administration. Despite the higher serum concentration, actual drug concentration in the liver is lower because of no first-pass effect of enteral drug entering the portal venous system. The onset of analgesia typically occurs within 5 to 10 minutes after IV administration which peaks at approximately 1 hour and lasts for 4 to 6 hours. Volume of distribution is 1.1 L/kg for neonates, 1.2 L/kg in children, and 0.8 L/kg in adults. In pharmacokinetic trials of the IV administration, neonates had the longest half-life, (7.0 ± 2.7 h); infants the shortest half-life (4.2 ± 2.9 h); and children, adolescents, and adults had similar half-lives (3.0 ± 1.5, 2.9 ± 0.7, and 2.4 ± 0.6 h, respectively). Because of the pharmacokinetic differences in neonates and infants compared with older children and adults the drug is not yet FDA cleared for this age group although the manufacturer suggests that the IV administered dose for neonates should be approximately 33% of the pediatric dose. The recommended dose for infants of less than 1 month to 2 years of age should be 50% of the pediatric dose. In both neonates and infants, a 6-hour dosing interval is recommended. The recommended pediatric dose (2 y and older) is 15 mg/kg IV q6h, with a maximum daily dose of 75 mg/kg/d. It has been shown that ketorolac and acetaminophen IV work additively and can be used together, with 60% reduction in fentanyl dose and 55% reduction in incidence of opioid side effects postoperatively for the same analgesia as opioid alone. 22 In our institution, we have significant success with the combined administration of IV ketorolac and acetaminophen in reducing opioid dosing and opioid-related serious adverse effects such as respiratory depression and profound sedation. At present, our institutional policy restricts IV acetaminophen to maximum of 3 days of around the clock dosing, after which liver function tests are performed if therapy is to be continued, especially in malnourished and severely ill children. In a retrospective study conducted at our institution, among children undergoing spine and colorectal surgery patients receiving PCA with or without IV acetaminophen, we found that IV acetaminophen significantly decreased opioid requirements without any significant increase in liver enzymes after 3 days of dosing (oral personal communications, Sadhasivam S, MD, 2012). Experience from Europe indicates that serious and even fatal dosing errors (10-fold dosing) can occur in small children. In the setting of IV acetaminophen dosing errors, Dart and colleagues recommends that a serum acetaminophen concentration should be drawn 4 hours after the dose or as soon thereafter as possible. If the serum acetaminophen concentration plots above the treatment line on the Rumack-Matthew nomogram, treatment with acetylcysteine should be initiated. 23 IV lidocaine has also been used as an analgesic adjunct in adults in doses of 1.5 mg/kg bolus and 1.5 mg/kg/h infusion intraoperatively and sometimes postoperatively for postoperative pain control. Being a local anesthetic, it has analgesic, anti-inflammatory, and antihyperalgesic properties, and was found to improve patient rehabilitation and reduce hospital stay. 24 Although there are no published studies in children, IV lidocaine has been used successfully for providing analgesia in a child who was terminally ill. 25 Tapentadol is a novel analgesic on the horizon, with combined m-opioid agonist and noradrenergic reuptake inhibition activity that provides effective analgesia for acute pain with both nociceptive and neuropathic components, but with reduced gastrointestinal side effects than oxycodone in adults. Unlike tramadol, it does not go through CYP2D6 eliminating unpredictable risk of respiratory depression in ultrarapid metabolizers. This drug is not FDA approved in children and is being investigated.
'

Developmental Pharmacology and Neurobiology on Pain Management
With the rapid growth of knowledge in infant neurobiology, longheld concepts about lack of pain perception in the fetus and newborn, have been challenged. Fetal stress in response to painful stimuli has been shown by increase in fetal cortisol, noradrenaline, and b-endorphin concentrations after intrahepatic vein needling in fetuses of 20 to 34 weeks of gestation. 26 The obliteration of this response by the administration of opioids to the fetus, suggest an analgesic effect. 27 It has been debated whether fetal movement, withdrawal reflexes, or hormonal stress response to invasive procedures prove the existence of fetal pain, because they can be elicited by nonpainful stimuli and occur without conscious cortical processing. 28 Current evidence suggests that the development of the subcortex is sufficient to render an integrated sensation of nociception in the fetus. 29 As thalamocortical connections begin appearing between 20 and 30 weeks gestational age, the anatomic structures and the physiological mechanisms for pain perception are established by early second trimester. 30 Because specific connections in the pain pathway are immature in the newborn, the receptive field areas in the dorsal horn of the spinal cord that respond to stimulation are relatively large. Moreover, inhibiting descending input from the brain is nonfunctional in the first few weeks of life. 31 This results in primary spinal and supraspinal central sensitization from injury with potentially long-lasting effects such as persistent hyperalgesia and allodynia in adulthood. 32 In a landmark study, Anand et al 33 showed that preterm babies undergoing patent ductus arteriosus ligation mount a substantial stress response to surgery under anesthesia, and prevention of this response by fentanyl is associated with an improved postoperative outcome. In another study of full-term infants, it was noted that the pain experienced during circumcision as newborns influences the pain responses to vaccination as infants. Uncircumcised infants had lower pain responses compared with infants who were circumcised with topical anesthetic, whose pain responses were lower than those who were circumcised without analgesia, suggesting long-lasting effects of pain experienced in early life. 34 Hence, anesthesia and analgesia for fetal surgery (mid-gestation and beyond), preterm and full-term neonates undergoing painful procedures is necessary. 35 In contrast to the benefits of opioids in neonatal surgery, recent studies suggest the potential neurotoxicity of anesthetics and analgesics on the developing brain. Studies in neonatal rats (days 1 to 7 after birth) found adverse long-term effects of morphine in the adult rats including retarded motor development and decreased brain metabolism. 36 Opioid signaling modulates cell cycle progression of neuronal and glial progenitor cells in the developing cerebral cortex in vivo. 37 In vitro studies show apoptosis of human neurons and microglial cells after morphine exposure, which was blocked by naloxone, indicating an opiate receptor mechanism. 38 Morphine dosing also displays a specific effect on hypothalamic nuclei with detrimental effects on pituitary hormone release and thyroid function. 39 These results suggest harmful effects of morphine on neurogenesis in newborn babies, but evidence from human trials is nonexistent. A cohort of preterm neonates (less than 34 wk of gestational age) was assigned randomly to 3 groups-morphine infusion, pancuronium only, and morphine+pancuronium to facilitate mechanical ventilation. All groups were evaluated for intelligence, motor abilities, and behavior at 5 to 6 years of age. There were no differences between groups, revealing no detrimental effects of morphine on neurocognitive behavior. 40 Another recent study investigated the effects of morphine versus placebo infusions administered in the first 3 days of life in neonates of less than 32 weeks of gestational age on intelligence, visual motor integration, behavior, chronic pain, and health-related quality of life at the age 5 years. Although a trend towards a more negative outcome was associated with more morphine in the first 28 days of life, a statistically significant association existed between worse performance on the "visual analysis" subtest of the IQ test and neonatal morphine consumption. 41 Of note, the centrally acting a-2-adrenergic agonist, dexmedetomidine, used as an analgesic prevented neurodegenerative apoptosis in immature brains of rodents. 42 This suggests that reduced opioid use and the use of analgesic adjuvants like dexmedetomidine may provide a neuroprotective effect in neonates. The National Birth Defects Prevention Study, a population-based casecontrol study, examined whether maternal opioid treatment between 1 month before pregnancy and the first trimester was associated with birth defects. Similar to previous studies, they found that codeine and hydrocodone were associated with an increased incidence of congenital heart defects. 43 Although opioids perinatally may affect adversely the development of vital organ systems in the fetus, further studies are needed to account for confounding factors and to understand causation before changing clinical practice.
'
Pharmacogenetics Affecting Analgesia
"Pharmacogenetics" is defined as "the study of genetic variations affecting drug response." It is sometimes used interchangeably with the word "pharmacogenomics," which is defined as "the broader application of genomic technologies to drug discovery, pharmacokinetics, pharmacodynamics, and therapeutic outcomes." As the genetic code determines the structure of proteins by a process of transcription and translation, variability in the genetic code (Single Nucleotide Polymorphisms or SNPs, mutations, etc.) alter proteins that make up the enzymes, drug receptors, and transporters regulating the pharmacokinetics and pharmacodynamics of drugs. The progression of DNA to RNA to protein that in turn determines the pharmacology, is not as simple as it seems. Several million unique proteins are coded for by this limited genome of 20,000 to 30,000 genes. Thus, a gene is able to encode for >1 protein. Different cells and tissues express the same genes differently, resulting in different protein expressions for the same gene. "Epigenetics" is the study of the mechanisms of temporal and spatial control of gene activity. 44 The molecular basis involves modification of gene activation, not modification of the actual structure of the DNA, by small noncoding RNAs called microRNA, which are in turn modulated by DNA methylation and chromatin structure. 45 "Proteomics" is the study of the full repertoire of proteins encoded by the genome in a given cell, tissue, or organism and "metabolomics" is the "systematic study of the unique chemical fingerprints that specific cellular processes leave behind" that also provides more specific information. One of the challenges of functional genomics is to integrate proteomic, transcriptomic, and metabolomic information to give a more complete picture of individual response.
The influence of pharmacogenetics on effects of analgesic drugs can be summarized as (1) effects on pain perception; (2) effects on opioid pharmacokinetics and pharmacodynamics; and (3) effects on nonopioid analgesia. For a more detailed review, please refer to our review article. 46 Another related factor is race. Among children undergoing tonsillectomy, African American children experienced greater postoperative pain, and white children experienced greater incidence of opioid-related adverse effects. 47 African American children displayed higher morphine clearance and morphine-3-glucuronide to morphine-6-glucuronide ratios than white children. In preliminary studies, common uridine glucurunosyl transferase (UGT2B7) genetic variations (À 161C > T and 802C > T) were not associated with racial differences in morphine's clearance even though the wild-type of the UGT2B7 isozyme is more prevalent in the African Americans. 48 
Nonopioid Analgesics and Developmental Pharmacogenetics
Acetaminophen (APAP): APAP is bioactivated to the reactive intermediate, N-acetyl-p-benzoquinoneimine (NAPQI) by 3 CYP 450 isoforms: CYP3A4, CYP2E1, and CYP1A2. 49 NAPQI then undergoes conjugation with glutathione to form a nontoxic conjugate. Depletion of glutathione stores causes NAPQI to bind with thiols leading to hepatocellular necrosis. 50 Developmental pharmacology studies indicate that CYP3A4 and CYP1A2 activity in 12-to 48-month-old children exceed younger and older children, making the 12 to 48 month olds prone to APAP hepatotoxicity. This is offset by an increased capacity to conjugate the drug with sulfates, providing "relative protection" against acute APAP intoxication. Nevertheless, true polymorphisms of glutathione transferase exist and individuals with the poor metabolizer phenotype are at increased risk of APAP-induced hepatotoxicity 51 NSAID: Ketorolac does appear to significantly penetrate cerebrospinal fluid in children, unlike adults. The MDR-1 gene has been suggested as the transport factor for ketorolac to cross the blood brain barrier.
Animal studies have shown that developmental differences in COX-1 expression in the spinal cord explain the lack of efficacy of COX-1 inhibitors in 3 day-old rat pups compared with 21-day-old rat pups. 53 Should similar developmental expression of COX-1 occur in humans, COX-1 inhibitors such as NSAID and APAP may exhibit reduced efficacy in neonates. 54 The role of pharmacogenetics in drug response has been rapidly evolving. Genetic factors account for 20% to 95% of drug response variability; 59% of drugs having adverse reactions are metabolized by at least 1 enzyme with a variant allele associated with poor metabolism. 55 Presently, the FDA has approved pharmacogenetic warnings in the labels of over 100 drugs, including analgesics like codeine, tramadol/ acetaminophen combinations, and celecoxib.
56 Table 1 depicts the pharmacological effects of genetic variations on opioid analgesia. OPRM1 118G variations reduces opioid signaling and increases morphine dose requirement. The presence of the V158M variant of the catechol-O-methyl transferase (COMT) coded by the 472G > A SNP leads to a low-function COMT enzyme that fails to degrade dopamine, leading to a depletion of encephalin and compensatory upregulation of opioid receptor expression. Besides, presence of Z2 nonfunctional Melanocortin Receptor (MC1R) variants resulted in impaired G-protein coupling and decreased function of MC1R receptors leading to a sex nonspecific increase in potency of m-opioid agonists. Lotsch and Geisslinger have suggested simple genotype tailored morphine dosing ranging from 0.4 to 2 times the dose of morphine required for equivalent analgesia in those without the gene variant ( Â2 for OPRM1 118G, Â 0.67 for COMT 472A, Â 0.67 for 2 MC1R nonfunctional SNPs and multiplicative model for multiple SNPs), 74 and this has not been validated in different pain phenotypes and populations. Hence, it remains a futuristic challenge to validate genotype-phenotype associations and incorporate them into the decision-making process of drug and dose selection, to make personalized analgesia a practicable reality and not just a distant dream.
'
Summary
Acute surgical pain management in children is best addressed by a dedicated pain management team. Although PCA with opioids forms the main modality of analgesia, regional techniques have gained popularity. PCA by proxy and PCA basal infusions enhance analgesia but carry a risk for respiratory depression and sedation. Efficient prevention of opioid-induced respiratory depression requires the use of appropriate monitoring including pulsoximetry and respiratory rate, clinical sedation scoring system, repeated assessment by the pain team, early intervention protocols, and use of nonopioid adjuncts like IV or oral acetaminophen and ketorolac/NSAIDs. Thalamocortical connections underpinning the neuroanatomy of pain appear between 20 and 30 weeks of gestational age, and the physiological mechanisms for pain perception become established by early second trimester. There are long-lasting effects of pain experienced in early life underscoring the need to treat surgical pain in fetuses, premature infants, and neonates. In contrast, there is a growing body of evidence in animal models implicating opioids in adversely altering neuronal proliferation in the developing brain and clinical studies wherein morphine sedation in the neonatal period was found to decrease visual motor integration in childhood, suggesting a potential for neurocognitive sequelae. Ongoing research provides hope that future integration of pharmacogenetics, metabolomics, and proteomics in clinical decision and analgesic selection/dosing processes will maximize analgesia and minimize adverse effects.
